Impact of CLSI breakpoint changes on microbiology laboratories and antimicrobial stewardship programs

Journal of Clinical Microbiology

Volumn 54, Issue 4, 2016, Pages 840-844

  Heil, Emily L ^a   Johnson, J Kristie ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL DECISION MAKING; CLINICAL LABORATORY; DRUG APPROVAL; DRUG PROGRAM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HEALTH CARE AVAILABILITY; LABORATORY TEST; MICROBIOLOGY LABORATORY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; DRUG THERAPY; DRUG UTILIZATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; STANDARDS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DRUG THERAPY; DRUG UTILIZATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84962591008     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02424-15     Document Type: Review

References (21)

1. CLSI. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement, CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
2. CLSI. 2014. Performance standards for antimicrobial susceptibility testing: 24th informational supplement, CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
3. The European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, 2015. http://www.eucast.org.
4. Marchaim D, Sunkara B, Lephart PR, Gudur UM, Bhargava A, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Chopra T, Dhar S, Kaye KS. 2012. Extended-spectrum beta-lactamase producers reported susceptible to piperacillin-tazobactam, cefepime and cefuroxime in the era of lowered breakpoints and no confirmatory test. Infect Control Hosp Epidemiol 33:853-855. http://dx.doi.org/10.1086/666632.
5. McWilliams CS, Condon S, Schwartz RM, Ginocchio CC. 2014. Incidence of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints. J Clin Microbiol 52:2653-2655. http://dx.doi.org/10.1128/JCM.03613-13.
6. Kristo I, Pitiriga V, Poulou A, Zarkotou O, Kimouli M, Poumaras S, Tsakris A. 2013. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum betalactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria. Int J Antimicrob Agents 41:383-387. http://dx.doi.org/10.1016/j.ijantimicag.2012.12.003.
7. Dudley MN, Ambrose PG, Bhavnani SM. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 56:1301-1309. http://dx.doi.org/10.1093/cid/cit017.
8. Thomson KS, Moland ES. 2001. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrumβ-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 45:3548-3554. http://dx.doi.org/10.1128/AAC.45.12.3548-3554.2001.
9. Kang C, Cha MK, Kim SO, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. 2014. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Int J Antimicrob Agents 43:456-459. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.030.
10. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2004. Bloodstream infections due to extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574-81. http://dx.doi.org/10.1128/AAC.48.12.4574-4581.2004.
11. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum betalactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206-2212.
12. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. 2012. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrumβ-lactamases: A systematic review and meta-analysis. J Antimicrob Chemother 67:2793-2803. http://dx.doi.org/10.1093/jac/dks301.
13. Nguyen HM, Shier KL, Graber CJ. 2014. Determining a clinical framework for use of cefepime andβ-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 69:871-880. http://dx.doi.org/10.1093/jac/dkt450.
14. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. 2013. Cefepime therapy for monomicrobial bacteremia caused by cefepimesusceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 56:488-495. http://dx.doi.org/10.1093/cid/cis916.
15. Kallen AJ, Beekmann SE, Limbago B, Lentnek AL, Polgreen PM, Patel J, Srinivasan A. 2011. Prevalence of beta-lactam nonsusceptible Gramnegative bacilli and use and interpretation of current susceptibility breakpoints: A survey of infectious disease physicians. Diagn Microbiol Infect Dis 71:316-319. http://dx.doi.org/10.1016/j.diagmicrobio.2011.07.013.
16. Liu PY, Shi ZY, Tung KC, Shyu CL, Chan KW, Liu JW, Wu ZY, Kao CC, Huang YC, Lin CF. 2014. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: The effects of altering clinical breakpoints. J Infect Dev Ctries 8:289-296. http://dx.doi.org/10.3855/jidc.3335. 24619258.
17. Hombach M, Bloemberg GV, Bottger EC. 2012. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of gram-negative bacilli. J Antimicrob Chemother 67:622-632. http://dx.doi.org/10.1093/jac/dkr524.
18. Rhodes NJ, Liu J, McLaughlin MM, Qi C, Scheetz MH. 2015. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC. Diagn Microbiol Infect Dis 82:165-171. http://dx.doi.org/10.1016/j.diagmicrobio.2015.03.005.
19. Abbo LM, Cosgrove SE, Pottinger PS, Pereyra M, Sinkowitz-Cochran R, Srinivasan A, Webb DJ, Hooton TM. 2013. Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? Clin Infect Dis 57:631-638. http://dx.doi.org/10.1093/cid/cit370.
20. CLSI. 2009. Performance standards for antimicrobial susceptibility testing: 20th informational supplement, CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
21. CLSI. 2013. Performance standards for antimicrobial susceptibility testing: 20th informational supplement, CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.